Sale!

PRRT2 Gene Seizures Benign Familial Infantile Type 2 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The PRRT2 gene is associated with benign familial infantile seizures type 2, a condition characterized by early-onset seizures that typically manifest in infancy or early childhood. These seizures are usually brief and tend to resolve by the age of 2 to 4 years. The condition is inherited in an autosomal dominant manner, meaning a mutation in just one of the two copies of the gene can cause the disorder.

Genetic testing for mutations in the PRRT2 gene is crucial for accurate diagnosis and management of the condition. It helps in distinguishing benign familial infantile seizures from other types of epilepsy that may require different treatment approaches. Early and precise diagnosis can also provide valuable information for family planning and genetic counseling.

DNA Labs UAE offers a genetic test specifically designed to detect mutations in the PRRT2 gene. The test is conducted using a blood sample, and the process involves analyzing the genetic material to identify any alterations in the PRRT2 gene that are known to cause benign familial infantile seizures type 2.

The cost of the PRRT2 gene test at DNA Labs UAE is 4400 AED. This investment in genetic testing can be pivotal for families seeking answers to their child’s seizure disorder, enabling them to access targeted treatment and support, and to understand the risk for future children or other family members.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

PRRT2 Gene Seizures benign familial infantile type 2 Genetic Test

Components: Blood or Extracted DNA or One drop Blood on FTA Card

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test type: Neurological Disorders

Doctor: Neurologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for PRRT2 Gene Seizures, benign familial infantile, type 2 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with PRRT2 Gene Seizures, benign familial infantile, type 2.

Test Details

The PRRT2 gene is associated with a condition called benign familial infantile seizures, type 2 (BFIS2). BFIS2 is a rare genetic disorder characterized by seizures that typically begin in infancy and resolve by early childhood. These seizures are usually brief, lasting only a few seconds to a few minutes, and may involve involuntary movements such as tremors or muscle stiffness.

NGS (Next-Generation Sequencing) genetic testing is a method used to analyze multiple genes simultaneously to identify any genetic variations or mutations that may be associated with a particular condition. In the case of BFIS2, NGS genetic testing can be used to detect any mutations or variations in the PRRT2 gene that may be responsible for the seizures.

NGS genetic testing involves obtaining a DNA sample, usually through a blood sample or a cheek swab, from the individual undergoing testing. The DNA is then sequenced using advanced sequencing technologies, allowing for the identification of any genetic variations or mutations in the PRRT2 gene.

By identifying specific mutations or variations in the PRRT2 gene, NGS genetic testing can provide a definitive diagnosis for individuals with BFIS2. This can help guide treatment decisions and provide important information for family planning and genetic counseling.

It is important to note that NGS genetic testing is typically performed by healthcare professionals with expertise in genetics. The results of the test should be interpreted by a genetic counselor or medical geneticist to ensure accurate diagnosis and appropriate management of the condition.

Test Name PRRT2 Gene Seizures benign familial infantile type 2 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for PRRT2 Gene Seizures, benign familial infantile, type 2 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with PRRT2 Gene Seizures, benign familial infantile, type 2
Test Details

The PRRT2 gene is associated with a condition called benign familial infantile seizures, type 2 (BFIS2). BFIS2 is a rare genetic disorder characterized by seizures that typically begin in infancy and resolve by early childhood. These seizures are usually brief, lasting only a few seconds to a few minutes, and may involve involuntary movements such as tremors or muscle stiffness.

NGS (Next-Generation Sequencing) genetic testing is a method used to analyze multiple genes simultaneously to identify any genetic variations or mutations that may be associated with a particular condition. In the case of BFIS2, NGS genetic testing can be used to detect any mutations or variations in the PRRT2 gene that may be responsible for the seizures.

NGS genetic testing involves obtaining a DNA sample, usually through a blood sample or a cheek swab, from the individual undergoing testing. The DNA is then sequenced using advanced sequencing technologies, allowing for the identification of any genetic variations or mutations in the PRRT2 gene.

By identifying specific mutations or variations in the PRRT2 gene, NGS genetic testing can provide a definitive diagnosis for individuals with BFIS2. This can help guide treatment decisions and provide important information for family planning and genetic counseling.

It is important to note that NGS genetic testing is typically performed by healthcare professionals with expertise in genetics. The results of the test should be interpreted by a genetic counselor or medical geneticist to ensure accurate diagnosis and appropriate management of the condition.